Daratumumab Combo Improves PROs for Patients with Newly Diagnosed MM

Published by W Butcher on

Research in the Journal of Clinical Oncology found an association between the combination of daratumumab, lenalidomide, and dexamethasone with improved patient-reported outcomes versus lenalidomide and dexamethasone alone. Compared with lenalidomide (Revlimid) and dexamethasone (Rd) alone, the combination with the addition of daratumumab (Darzalex) (D-Rd) for the treatment of transplant-ineligible, newly diagnosed multiple myeloma was associated with improved patient-reported outcomes (PROs), according to data published in the Journal of Clinical Oncology.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.